Dranitsaris G, Longo CJ, Grossman L; International Society of Technology Assessment in Health Care. Meeting.

Annu Meet Int Soc Technol Assess Health Care Int Soc Technol Assess Health Care Meet. 2000; 16: 115.

Department of Pharmaceutical Services, The University Health Network, and Eli Lilly Canada Inc., Toronto, Canada

Poorly controlled diabetes is a major risk factor for heart and kidney disease, blindness, leg amputations and impotence. A recent randomised cross-over trial demonstrated that Humalog Mix 25 (Eli Lilly and Company Inc.), a new formulation consisting of rapid acting insulin lispro and intermediate acting NPL in a 25/75 ratio, significantly reduced postprandial blood glucose excursions and the number of nocturnal hypoglycemic episodes relative to human 30/70 insulin. To measure the economic value of the new product, a cost-benefit analysis using a consumer based Willingness-to-Pay (WTP) approach was conducted from a Canadian payer perspective. The final study sample consisted of 80 Canadian taxpayers from Ontario and Quebec selected using a systematic multistage random sampling technique with geographic clustering, yielding a 64% response rate. After background information on the differences between Humalog Mix 25 and human 30/70 insulin were presented, respondents were asked their preferred product if they were diagnosed with diabetes. Respondents were then asked the maximum premium that they would pay per month in the form of a user's fee for the insulin their choice. The WTP survey instrument was simple to administer and easily understood by participants. Approximately 84% of the sample preferred to use Humalog Mix 25 and were willing to pay for it (p = 0.012). The sample of tax-payers were willing to pay a mean of $Can35.28 (95%ci = $27.50 to $43.07) per month for the benefits offered by Humalog Mix 25, which was at least two-fold higher than its incremental monthly cost. The results of the study revealed that Canadians prefer to use Humalog Mix 25 instead of human 30/70 insulin and they would be willing to pay for it. Compared to other drugs, this overall net gain suggests that Humalog Mix 25 represents good value for money and should be considered for reimbursement by third party payers.

Publication Types:

• Meeting Abstracts

Keywords:

• Blood Glucose
• Canada
• Cost-Benefit Analysis
• Cross-Over Studies
• Data Collection
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Humans
• Insulin
• Male
• Ontario
• Postprandial Period
• Quality-Adjusted Life Years
• Quebec
• Taxes
• economics
• insulin LISPRO
• hsrmtgs

Other ID:

• GWHSR0000102

UI: 102271776

From Meeting Abstracts